FDA Approves Intravenous Formulation of Akynzeo (fosnetupitant/palonosetron) for Chemotherapy-Induced Nausea and Vomiting

Lugano, Switzerland April 20, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of Akynzeo...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news